Clearstead Advisors LLC Boosts Stock Position in Twist Bioscience Corporation $TWST

Clearstead Advisors LLC raised its stake in Twist Bioscience Corporation (NASDAQ:TWST) by 29,577.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,013 shares of the company’s stock after purchasing an additional 7,986 shares during the period. Clearstead Advisors LLC’s holdings in Twist Bioscience were worth $254,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also added to or reduced their stakes in the company. Thrivent Financial for Lutherans boosted its holdings in Twist Bioscience by 14.5% in the third quarter. Thrivent Financial for Lutherans now owns 1,463,085 shares of the company’s stock worth $41,171,000 after acquiring an additional 184,726 shares in the last quarter. EdgePoint Investment Group Inc. boosted its holdings in Twist Bioscience by 71.1% in the third quarter. EdgePoint Investment Group Inc. now owns 4,082,319 shares of the company’s stock worth $114,876,000 after acquiring an additional 1,696,377 shares in the last quarter. First Light Asset Management LLC boosted its holdings in Twist Bioscience by 26.4% in the third quarter. First Light Asset Management LLC now owns 1,194,883 shares of the company’s stock worth $33,624,000 after acquiring an additional 249,850 shares in the last quarter. SG Americas Securities LLC boosted its holdings in Twist Bioscience by 350.3% in the fourth quarter. SG Americas Securities LLC now owns 76,484 shares of the company’s stock worth $2,426,000 after acquiring an additional 59,500 shares in the last quarter. Finally, William Blair Investment Management LLC boosted its holdings in Twist Bioscience by 6.0% in the third quarter. William Blair Investment Management LLC now owns 4,142,283 shares of the company’s stock worth $116,564,000 after acquiring an additional 235,679 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a report on Friday, March 27th. Robert W. Baird raised their price target on Twist Bioscience from $50.00 to $65.00 and gave the stock an “outperform” rating in a report on Tuesday, May 5th. Barclays raised their price target on Twist Bioscience from $55.00 to $65.00 and gave the stock an “overweight” rating in a report on Monday, May 4th. Leerink Partners set a $80.00 price target on Twist Bioscience in a report on Friday, May 22nd. Finally, Guggenheim raised their price target on Twist Bioscience from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $58.00.

Insiders Place Their Bets

In other news, Director Robert Chess sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $47.00, for a total value of $470,000.00. Following the completion of the sale, the director directly owned 21,084 shares in the company, valued at $990,948. The trade was a 32.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Adam Laponis sold 4,000 shares of the business’s stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $60.00, for a total value of $240,000.00. Following the completion of the sale, the chief financial officer owned 118,694 shares of the company’s stock, valued at $7,121,640. This trade represents a 3.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 46,551 shares of company stock valued at $2,566,533. 3.08% of the stock is owned by insiders.

Twist Bioscience Trading Down 3.1%

Shares of NASDAQ:TWST opened at $66.87 on Friday. The company has a market capitalization of $4.16 billion, a PE ratio of -50.28 and a beta of 2.22. Twist Bioscience Corporation has a 12-month low of $23.30 and a 12-month high of $71.04. The business has a 50 day moving average of $54.62 and a two-hundred day moving average of $44.46. The company has a current ratio of 2.70, a quick ratio of 2.42 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Monday, May 4th. The company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.22). The business had revenue of $110.72 million during the quarter, compared to analysts’ expectations of $107.64 million. Twist Bioscience had a negative net margin of 19.85% and a negative return on equity of 26.73%. The firm’s quarterly revenue was up 19.3% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.66) earnings per share. As a group, analysts forecast that Twist Bioscience Corporation will post -1.86 EPS for the current year.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.